Th22细胞在慢性粒细胞白血病患者中的临床研究

Clinical study of Th22 cells in patients with chronic myeloid leukemia

目的:研究慢性粒细胞白血病(CML)患者外周血中Th22细胞的比例、相关转录因子芳香烃受体(AHR)的表达水平及细胞因子IL-22的浓度,探讨Th22细胞在CML免疫机制中的作用。方法:应用流式细胞术检测Th22细胞在33例CML患者(初诊15例,伊马替尼治疗后的CML-CP 18例)外周血中的比例,实时荧光定量PCR技术检测CML患者Th22相关转录因子AHR mRNA的表达水平,ELISA法检测细胞因子IL-22的浓度。同时以15例正常者作为对照。结果:CML初诊患者外周血的Th22细胞比例(0.43%±0.23%)明显低于伊马替尼治疗后的CML-CP患者(3.19%±1.76%,P<0.05)和对照者(2.58%±0.98%,P<0.05)。CML初诊患者外周血单个核细胞的AHR基因转录水平(0.212 9±0.174 6)与伊马替尼治疗后的CML-CP患者(0.817 1±0.388 7,P<0.05)和对照者(0.468 1±0.180 4,P<0.05)比较均明显降低。伊马替尼治疗后的CML-CP患者外周血AHR mRNA表达水平较对照者显著升高(P<0.05)。CML-CP患者的外周血IL-22浓度较对照者显著升高[(100.94±18.48)pg/ml∶(85.14±13.46)pg/ml,P<0.05]。Th22细胞的比例与CML患者外周血白细胞计数及BCR-ABL%均呈负相关。结论:Th22细胞下调,Th22免疫功能受损可能有助于CML的发生和发展。

Objective：To explore the ratio of Th22 cells,the expression of transcription factors AHR and their related cytokines IL-22 in peripheral blood of chronic myeloid leukemia（CML）patients,and to further investigate the role of Th22 cells in hematological tumor immune mechanisms.Method：The proportions of Th22 cells in peripheral blood of 33 patients with CML were evaluated by flow cytometry analysis.AHR mRNA expressions were examined by RT-PCR.The levels of cytokines IL-22 were measured by ELISA.Fifteen normal subjects were used as controls.Result：The ratio of Th22 cells was significantly decreased in newly-diagnosed CML（CML-NP）patients（0.43%±0.23%）than those in chronic phase CML（CML-CP）patients（3.19%±1.76%,P〈0.05）and controls（2.58%±0.98%,P〈0.05）.The expression of AHR was significantly decreased in CML-ND patients（0.212 9±0.174 6）compared with CML-CP patients（0.817 1±0.388 7,P〈0.05）and controls（0.468 1±0.180 4,P〈0.05）.The mRNA level of AHR was increased in CML-CP patients than that in controls（P〈0.05）.The level of IL-22 in CML-CP patients was slightly higher than controls[（100.94±18.48）pg/ml vs.（85.14±13.46）pg/ml,P〈0.05].There were significantly negative correlations between Th22 cells and peripheral white blood cell counts and BCR-ABL%.Conclusion：Down-regulation of Th22 cellular immunity and impaired Th22 immune function may contribute to the occurrence and development of CML.